Responses
Friday 07 October 2022 from 13:00 to 14:10
PO.5 E- poster session 5: lupus nephritis
PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis
Compose a Response to This Article
Other responses
No responses have been published for this article.